See more : Innovative MedTech Inc. (IMTH) Income Statement Analysis – Financial Results
Complete financial analysis of Minerva Surgical, Inc. (UTRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Minerva Surgical, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Europlasma S.A. (ALEUP.PA) Income Statement Analysis – Financial Results
- Cyviz AS (CYVIZ.OL) Income Statement Analysis – Financial Results
- Afry AB (AFRY.ST) Income Statement Analysis – Financial Results
- Le Saunda Holdings Limited (LESAF) Income Statement Analysis – Financial Results
- NAHL Group Plc (NHLPF) Income Statement Analysis – Financial Results
Minerva Surgical, Inc. (UTRS)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://minervasurgical.com
About Minerva Surgical, Inc.
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 50.29M | 52.10M | 37.77M | 26.01M |
| Cost of Revenue | 23.05M | 21.58M | 18.65M | 14.21M |
| Gross Profit | 27.24M | 30.52M | 19.12M | 11.81M |
| Gross Profit Ratio | 54.17% | 58.58% | 50.62% | 45.38% |
| Research & Development | 5.44M | 5.29M | 3.32M | 935.00K |
| General & Administrative | 14.37M | 22.18M | 8.21M | 8.38M |
| Selling & Marketing | 38.33M | 32.19M | 22.97M | 22.13M |
| SG&A | 52.70M | 54.38M | 31.19M | 30.51M |
| Other Expenses | 0.00 | -340.00K | 71.00K | 171.00K |
| Operating Expenses | 58.14M | 59.67M | 34.51M | 31.44M |
| Cost & Expenses | 81.19M | 81.25M | 53.16M | 45.65M |
| Interest Income | 89.00K | 10.00K | 81.00K | 135.00K |
| Interest Expense | 3.22M | 11.73M | 12.14M | 17.58M |
| Depreciation & Amortization | 10.81M | 10.29M | 7.23M | 1.98M |
| EBITDA | -20.07M | -18.86M | -8.16M | -17.66M |
| EBITDA Ratio | -39.91% | -36.19% | -21.61% | -67.88% |
| Operating Income | -30.90M | -29.15M | -15.39M | -19.64M |
| Operating Income Ratio | -61.44% | -55.94% | -40.75% | -75.49% |
| Total Other Income/Expenses | -3.20M | 7.69M | -3.01M | -32.41M |
| Income Before Tax | -34.10M | -21.46M | -18.40M | -52.05M |
| Income Before Tax Ratio | -67.80% | -41.18% | -48.71% | -200.08% |
| Income Tax Expense | 11.00K | 9.00K | -132.00K | 17.75M |
| Net Income | -34.11M | -21.46M | -18.26M | -69.80M |
| Net Income Ratio | -67.83% | -41.20% | -48.36% | -268.32% |
| EPS | -23.68 | -61.22 | -17.91 | -75.29 |
| EPS Diluted | -23.68 | -61.22 | -17.91 | -75.29 |
| Weighted Avg Shares Out | 1.44M | 350.61K | 1.02M | 927.03K |
| Weighted Avg Shares Out (Dil) | 1.44M | 350.61K | 1.02M | 927.03K |
Minerva Surgical, Inc. (UTRS) Q4 2022 Earnings Call Transcript
Minerva Surgical to Announce Fourth Quarter and Full Year 2022 Financial Results
Minerva Surgical to Present at the 41st Annual J.P. Morgan Healthcare Conference
Minerva Surgical to Present at the 34th Annual Piper Sandler Healthcare Conference
Minerva Surgical, Inc. (UTRS) Q3 2022 Earnings Call Transcript
Minerva Surgical Announces Change of Date for Third Quarter 2022 Earnings Release and Conference Call
Minerva Surgical to Announce Third Quarter 2022 Financial Results
Minerva Surgical to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Minerva Surgical, Inc. (UTRS) CEO Dave Clapper on Q2 2022 Results - Earnings Call Transcript
Minerva Surgical to Announce Second Quarter 2022 Financial Results
Source: https://incomestatements.info
Category: Stock Reports